CG Oncology Stock Falls 7% as RBC Downgrade Cools Rally After Bladder Cancer Drug Cuts Recurrence Risk by 68%
CG Oncology Inc. shares fell 7.53% on Tuesday, after a 14% rise on Monday following positive trial results for its bladder cancer treatment. RBC downgraded the stock to Sector Perform, citing regulatory path, despite raising its price target to $97. The Phase 3 trial showed a 68% reduction in cancer recurrence risk. Other analysts raised price targets, with JPMorgan at $113 and Truist at $100.
How this was made

The 30-second read
Why it matters
The key trade tension is between strong efficacy (68% recurrence-risk reduction, hazard ratio 0.32) and perceived regulatory-path complexity (broadened first application scope, two-step filing timeline).
Market read
Traders get a same-day sentiment reset: the stock’s rally on pivotal data is partially unwound by a regulatory-path downgrade, while the company’s filing plan provides a concrete timeline.
What to watch
The company plans to broaden the first marketing application based on FDA feedback and expects completion before end-March 2027, which could reduce uncertainty if FDA engagement is constructive.
Background
CG Oncology reported Phase 3 PIVOT-006 results for its bladder cancer oncolytic immunotherapy, then received a regulatory-path-focused downgrade from RBC.
Ticker impact
CG Oncology shares fell 7.53% after RBC downgraded the stock, citing the company’s regulatory path despite Phase 3 PIVOT-006 results.
Likely downside pressure or choppy trading as the market digests the downgrade and regulatory-path uncertainty, even with raised price targets from other analysts.
The article ties the same-day selloff to RBC’s downgrade and regulatory-path rationale, while also noting the company’s broadened FDA marketing application plan and upcoming late-breaking presentation.
Market effects
Reinforces how biotech investors can fade clinical success when regulatory strategy and label-expansion scope introduce execution risk.
Limited, as the story is company-specific and not a broad macro/regional catalyst.
Low beyond biotech investors tracking bladder cancer immunotherapy and oncolytic virus platforms.
Counterpoint
The RBC downgrade may be more about timing and label scope than efficacy, and other analysts’ higher success-probability estimates suggest the market may be over-discounting regulatory risk.
Key entities
- companyCG Oncology Inc.
Subject of the article; shares fell after RBC downgraded the stock despite Phase 3 PIVOT-006 meeting its primary goal.
- analyst_firmRBC Capital Markets
Downgraded CG Oncology to Sector Perform from Outperform, citing the company’s regulatory path, while raising its price target.
- analyst_firmJPMorgan
Raised its price target and kept Overweight after the trial data, increasing estimated probability of success.
- analyst_firmTruist Financial
Reiterated Buy and raised its target following the trial results.
- regulatorFDA
Provided feedback prompting CG Oncology to broaden its first marketing application scope.


